Work

Comment on “evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation”

Year: 2026

Type: article

Abstract: This correspondence acknowledges the authors' efforts in addressing an important clinical question and evaluating a practical dosing approach for patients undergoing hemodialysis. We highlight several methodological assumptions within the simulation model that may limit the clinical interpretability of the results, including the extrapolation of PK/PD targets from individuals with normal kidney function, the use of non-standard avibactam thresholds, and the unvalidated implications of prolonged sub-MIC intervals in hemodialysis populations. We further emphasize the need for dedicated PK/PD investigations and supporting clinical outcome data before these dosing strategies can be confidently integrated into practice.

Source: International Journal of Clinical Pharmacy

DOI: 10.1007/s11096-026-02127-x

Authors: Sarah Alhassan Aljumaa, Mohammed Al Musawa, Rania El Lababidi, Emna Abidi, Islam Ghazi, Wasim S. El Nekidy

Institutions: Cleveland Clinic Abu Dhabi, Long Island University, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Language: English

Topic: Antibiotics Pharmacokinetics and Efficacy

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,190